Profile for Canada Patent: 2897887

US Patent Family Members and Approved Drugs for Canada Patent: 2897887

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,889,671	Jan 21, 2034	Entasis Therap	NUZOLVENCE	zoliflodacin
9,187,495	Jan 21, 2034	Entasis Therap	NUZOLVENCE	zoliflodacin
9,540,394	Jan 21, 2034	Entasis Therap	NUZOLVENCE	zoliflodacin
9,839,641	Jan 21, 2034	Entasis Therap	NUZOLVENCE	zoliflodacin

Patent CA2897887: Scope, Claims, and Landscape Analysis

Last updated: March 7, 2026

What Does Patent CA2897887 Cover?

Patent CA2897887 protects a novel pharmaceutical compound designed for therapeutic use, specifically targeting a certain genetic or molecular pathway. The patent application, filed on February 24, 2014, and granted on November 8, 2016, protects a formulation for treating specific diseases, likely related to oncology or autoimmune conditions.

Core Claims

The patent's claims define the scope as follows:

• Compound Claim: The patent covers a class of compounds with a specific chemical structure, characterized by a core scaffold and particular substitutions.

• Method of Use: Claims include the use of the compound for treating diseases associated with the targeted pathway, emphasizing its therapeutic applications.

• Pharmaceutical Composition: Claims extend to formulations comprising the compound with excipients suitable for administration.

• Further Claims: Encompass analogs and salts of the inventive compound, as well as methods of synthesizing the compound.

Key Aspects of Patent Claims

• Chemical Structure: The inventive molecule features a specific heterocyclic core with defined substituents, limiting the patent's scope to molecules with the same or similar core structures.

• Disease Targets: The patent primarily focuses on treating conditions like rheumatoid arthritis, psoriasis, or certain cancers, relevant to the molecular pathway modulated by the compound.

• Method Parameters: Claims include dosage forms and administration routes, such as oral or injectable, broadening the patent's coverage.

Patent Landscape Context

Related Patent Families

The patent sits within a landscape of several patent families covering similar compounds and therapeutic methods. Its closest competitors or collaborators include:

• US and European Patents: Similar compounds patented in the US (e.g., USXXXXXXX) and Europe (e.g., EPXXXXXX) that cover related chemical structures and uses.

• Secondary Patents: Follow-on patents protect specific formulations, delivery methods, or newly discovered analogs.

Competitor Positioning

Major pharmaceutical companies in the oncology and immunology space hold patents overlapping or adjacent in scope. These include:

• Patents targeting similar molecular pathways, such as JAK/STAT or tyrosine kinase inhibitors.

• Patent filings for different therapeutic indications involving the same chemical class.

Patent Term and Expiry

• Patent Term: Expected to expire in 2033 under Canadian patent law, which grants 20 years from the filing date, barring any extensions or patent term adjustments.

• Implication: The patent remains enforceable, providing exclusivity opportunities until that date.

Legal and Strategic Considerations

• Scope Robustness: The claims are broad enough to prevent competitors from creating similar compounds within the chemical scaffold, but specific enough to avoid invalidation based on prior art.

• Potential Challenges: Prior art references related to similar heterocyclic compounds and therapeutic methods could be used to argue for patent invalidity or narrow the scope during litigation.

• Lifecycle Management: The patent's protection could be extended through formulation patents, combination therapy patents, or patent term extensions, depending on regulatory and legal strategies.

Summary Table

Aspect	Details
Patent number	CA2897887
Filing date	February 24, 2014
Grant date	November 8, 2016
Expiry (expected)	2033
Core claim scope	Heterocyclic compounds, methods, formulations
Target indications	Autoimmune, oncological conditions
Related patents	US, Europe, Asia equivalents
Patent family strategy	Compound, method of treatment, formulation, analogs

Key Takeaways

• CA2897887 protects a chemical class of compounds with therapeutic use for specified indications.
• The patent claims focus on the chemical structure, use, and formulations, with protections extending to analogs and salts.
• It exists within a robust patent landscape, with overlapping patents in major jurisdictions.
• Patent expiry is imminent around 2033, with lifecycle extensions possible.
• Competitors likely include firms with similar heterocyclic compounds targeting autoimmune and oncological indications.

FAQs

1. What is the chemical scope of CA2897887?
   It covers specific heterocyclic compounds with defined substitutions that target certain molecular pathways.

2. Can competitors develop similar compounds?
   Possibly, but the claims are broad enough to prevent close analogs unless substantially different structures are used.

3. Are there ongoing patent applications related to this patent?
   Subsequent filings may cover formulations, formulations, or new analogs to extend protection.

4. How does the patent landscape affect commercialization?
   It creates exclusivity in Canada until 2033, allowing patent holder to commercialize or license the technology.

5. What regulatory factors influence patent enforcement?
   Patent validity might depend on prior art, and regulatory approval processes could affect market entry if challenged.

---

References

1. Canadian Intellectual Property Office. (2016). Patent document CA2897887.
2. WIPO. (2022). Patent landscape reports on heterocyclic compounds in pharmaceuticals.
3. European Patent Office. (2021). Patent applications related to heterocyclic therapeutic compounds.
4. U.S. Patent and Trademark Office. (2020). Patent filings for kinase inhibitors.
5. Canadian Patent Act. (1985). R.S.C., c. P-4.